EGFR and lung adenocarcinoma: In Ontario, testing for predictive biomarkers including EGFR for lung adenocarcinoma, BRAF in malignant melanoma and KRAS and BRAF in metastatic colorectal cancer supports the use of targeted therapies for these patients.